| Literature DB >> 21859103 |
Mark S Dunstan1, John Barnes, Matthew Humphries, Roger C Whitehead, Richard A Bryce, David Leys, Ian J Stratford, Karen A Nolan.
Abstract
Imidazoacridin-6-ones are shown to be potent nanomolar inhibitors of the enzyme NQO2. By use of computational molecular modeling, a reliable QSAR was established, relating inhibitory potency with calculated binding affinity. Further, crystal structures of NQO2 containing two of the imidazoacridin-6-ones have been solved. To generate compounds with reduced off-target (DNA binding) effects, an N-oxide moiety was introduced into the tertiary aminoalkyl side chain of the imidazoacridin-6-ones. This resulted in substantially less toxicity in a panel of eight cancer cell lines, decreased protein binding, and reduced DNA binding and nuclear accumulation. Finally, one of the N-oxides showed potent ability to inhibit the enzymatic function of NQO2 in cells, and therefore, it may be useful as a pharmacological probe to study the properties of the enzyme in vitro and in vivo.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21859103 DOI: 10.1021/jm200416e
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446